Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AREDS2 in Age-Related Macular Degeneration
NCT00345176Phase 3Completed
- Sponsor
- National Eye Institute
- Start
- Sep 2006
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutein, OmniXan, docosahexaenoic acid, eicosapentaenoic acid in age-related macular degeneration (AMD), sponsored by National Eye Institute. Started Sep 2006; status: completed.
02
Drugs
luteinOmniXandocosahexaenoic acideicosapentaenoic acid
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00345176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00345176.